Literature DB >> 18457616

The enigmas of the lupus anticoagulant: mechanisms, diagnosis, and management.

Richard A Marlar1, Sanam Husain.   

Abstract

Lupus anticoagulant (LA) is a laboratory abnormality associated with the antiphospholipid syndrome. It is a paradoxical phenomenon in which one or more in vitro diagnostic clotting tests are prolonged and thus seem due to an anticoagulant, whereas the antiphospholipid syndrome is manifest clinically as inappropriate or excessive thrombosis. LA should be suspected when thrombosis, recurrent fetal loss, or a prolonged phospholipid (PL)-dependent clotting test is present without other identifiable causes. Despite the heterogeneity of LA antibodies, a consensus has evolved to identify the LA. Four conditions must be met for this laboratory diagnosis: 1) prolongation of a PL-based clotting test, 2) confirmation of an inhibitor-like pattern in the clotting test, 3) confirmation of PL dependence in coagulation tests, and 4) exclusion of a specific factor inhibitor. Even with an extensive armamentarium for LA diagnosis and treatment, it is still a formidable task.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18457616     DOI: 10.1007/s11926-008-0013-x

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  52 in total

1.  Evaluation of the phospholipid-rich dilute Russell's viper venom assay to monitor oral anticoagulation in patients with lupus anticoagulant.

Authors:  Jim Thom; Leesa Ivey; Grace Gilmore; John W Eikelboom
Journal:  Blood Coagul Fibrinolysis       Date:  2004-06       Impact factor: 1.276

Review 2.  Development of consensus guidelines for anticardiolipin and lupus anticoagulant testing.

Authors:  Richard C W Wong; Stephen Adelstein; David Gillis; Emmanuel J Favaloro
Journal:  Semin Thromb Hemost       Date:  2005-02       Impact factor: 4.180

Review 3.  Pathophysiology of the antiphospholipid syndrome.

Authors:  P G de Groot; R H W M Derksen
Journal:  J Thromb Haemost       Date:  2005-08       Impact factor: 5.824

4.  A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS).

Authors:  G Finazzi; R Marchioli; V Brancaccio; P Schinco; F Wisloff; J Musial; F Baudo; M Berrettini; S Testa; A D'Angelo; G Tognoni; T Barbui
Journal:  J Thromb Haemost       Date:  2005-05       Impact factor: 5.824

Review 5.  Current concepts on the pathogenesis of the antiphospholipid syndrome.

Authors:  Bill Giannakopoulos; Freda Passam; Soheila Rahgozar; Steven A Krilis
Journal:  Blood       Date:  2006-09-19       Impact factor: 22.113

Review 6.  Antiphospholipid syndrome: association between laboratory tests and clinical practice.

Authors:  Monica Galli
Journal:  Pathophysiol Haemost Thromb       Date:  2003 Sep-2004 Dec

7.  The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  Jack Ansell; Jack Hirsh; Leon Poller; Henry Bussey; Alan Jacobson; Elaine Hylek
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

8.  beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome.

Authors:  H Bas de Laat; Ronald H W M Derksen; Rolf T Urbanus; Mark Roest; Philip G de Groot
Journal:  Blood       Date:  2004-08-17       Impact factor: 22.113

9.  Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep.

Authors:  Hong Zhou; Alisa S Wolberg; Robert A S Roubey
Journal:  Blood       Date:  2004-06-29       Impact factor: 22.113

Review 10.  Activated protein C.

Authors:  J H Griffin; J A Fernández; A J Gale; L O Mosnier
Journal:  J Thromb Haemost       Date:  2007-07       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.